FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197476069> ?p ?o ?g. }

• W3197476069 endingPage "S409" @default.
• W3197476069 startingPage "S409" @default.
• W3197476069 abstract "Context Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. Objective This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Design Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. Results CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. Conclusions CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178]. Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178]." @default.
• W3197476069 created "2021-09-13" @default.
• W3197476069 creator A5046779901 @default.
• W3197476069 creator A5048841778 @default.
• W3197476069 creator A5065433271 @default.
• W3197476069 creator A5066084730 @default.
• W3197476069 creator A5089850088 @default.
• W3197476069 date "2021-09-01" @default.
• W3197476069 modified "2023-10-16" @default.
• W3197476069 title "MCL-363: Overexpression of CDC20 Promotes Cancer Progression in Mantle Cell Lymphoma" @default.
• W3197476069 doi "https://doi.org/10.1016/s2152-2650(21)01921-2" @default.
• W3197476069 hasPublicationYear "2021" @default.
• W3197476069 type Work @default.
• W3197476069 sameAs 3197476069 @default.
• W3197476069 citedByCount "0" @default.
• W3197476069 crossrefType "journal-article" @default.
• W3197476069 hasAuthorship W3197476069A5046779901 @default.
• W3197476069 hasAuthorship W3197476069A5048841778 @default.
• W3197476069 hasAuthorship W3197476069A5065433271 @default.
• W3197476069 hasAuthorship W3197476069A5066084730 @default.
• W3197476069 hasAuthorship W3197476069A5089850088 @default.
• W3197476069 hasConcept C105696609 @default.
• W3197476069 hasConcept C1491633281 @default.
• W3197476069 hasConcept C190283241 @default.
• W3197476069 hasConcept C199835354 @default.
• W3197476069 hasConcept C203014093 @default.
• W3197476069 hasConcept C2777525834 @default.
• W3197476069 hasConcept C2779338263 @default.
• W3197476069 hasConcept C2781018059 @default.
• W3197476069 hasConcept C29537977 @default.
• W3197476069 hasConcept C502942594 @default.
• W3197476069 hasConcept C54355233 @default.
• W3197476069 hasConcept C62112901 @default.
• W3197476069 hasConcept C86803240 @default.
• W3197476069 hasConceptScore W3197476069C105696609 @default.
• W3197476069 hasConceptScore W3197476069C1491633281 @default.
• W3197476069 hasConceptScore W3197476069C190283241 @default.
• W3197476069 hasConceptScore W3197476069C199835354 @default.
• W3197476069 hasConceptScore W3197476069C203014093 @default.
• W3197476069 hasConceptScore W3197476069C2777525834 @default.
• W3197476069 hasConceptScore W3197476069C2779338263 @default.
• W3197476069 hasConceptScore W3197476069C2781018059 @default.
• W3197476069 hasConceptScore W3197476069C29537977 @default.
• W3197476069 hasConceptScore W3197476069C502942594 @default.
• W3197476069 hasConceptScore W3197476069C54355233 @default.
• W3197476069 hasConceptScore W3197476069C62112901 @default.
• W3197476069 hasConceptScore W3197476069C86803240 @default.
• W3197476069 hasLocation W31974760691 @default.
• W3197476069 hasOpenAccess W3197476069 @default.
• W3197476069 hasPrimaryLocation W31974760691 @default.
• W3197476069 hasRelatedWork W2013115645 @default.
• W3197476069 hasRelatedWork W2348417465 @default.
• W3197476069 hasRelatedWork W2350294409 @default.
• W3197476069 hasRelatedWork W2586385055 @default.
• W3197476069 hasRelatedWork W2603514313 @default.
• W3197476069 hasRelatedWork W2808352915 @default.
• W3197476069 hasRelatedWork W2885613938 @default.
• W3197476069 hasRelatedWork W2889145277 @default.
• W3197476069 hasRelatedWork W2896912519 @default.
• W3197476069 hasRelatedWork W3190366649 @default.
• W3197476069 hasVolume "21" @default.
• W3197476069 isParatext "false" @default.
• W3197476069 isRetracted "false" @default.
• W3197476069 magId "3197476069" @default.
• W3197476069 workType "article" @default.